BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 18074758)

  • 1. Clinical study on the effect of simvastatin on paraoxonase activity.
    Muacević-Katanec D; Bradamante V; Poljicanin T; Reiner Z; Babić Z; Simeon-Rudolf V; Katanec D
    Arzneimittelforschung; 2007; 57(10):647-53. PubMed ID: 18074758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients.
    Tomás M; Sentí M; García-Faria F; Vila J; Torrents A; Covas M; Marrugat J
    Arterioscler Thromb Vasc Biol; 2000 Sep; 20(9):2113-9. PubMed ID: 10978257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of statin therapy on plasma high-density lipoprotein cholesterol levels is modified by paraoxonase-1 in patients with familial hypercholesterolaemia.
    Himbergen TM; van Tits LJ; Voorbij HA; de Graaf J; Stalenhoef AF; Roest M
    J Intern Med; 2005 Nov; 258(5):442-9. PubMed ID: 16238680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
    J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of simvastatin on high density lipoprotein subfractions and apolipoproteins in type IIa hypercholesterolemia.
    Crook D; Bruce R; Worthington M; Mulcahy D; Patterson D; Wynn V
    Cardiovasc Drugs Ther; 1992 Dec; 6(6):633-9. PubMed ID: 1292582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDL3 stimulates paraoxonase 1 antiatherogenic catalytic and biological activities in a macrophage model system: in vivo and in vitro studies.
    Rosenblat M; Volkova N; Aviram M
    Biofactors; 2014; 40(5):536-45. PubMed ID: 25230879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia.
    Steinmetz A; Schwartz T; Hehnke U; Kaffarnik H
    J Cardiovasc Pharmacol; 1996 Apr; 27(4):563-70. PubMed ID: 8847874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.
    Durrington PN; Mackness MI; Bhatnagar D; Julier K; Prais H; Arrol S; Morgan J; Wood GN
    Atherosclerosis; 1998 May; 138(1):217-25. PubMed ID: 9678787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of combination therapy with estrogen plus simvastatin on lipoprotein metabolism in postmenopausal women with type IIa hypercholesterolemia.
    Wakatsuki A; Okatani Y; Ikenoue N
    Atherosclerosis; 2000 May; 150(1):103-11. PubMed ID: 10781640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma lipoprotein distribution and lipid transfer activities in patients with type IIb hyperlipidemia treated with simvastatin.
    Lagrost L; Athias A; Lemort N; Richard JL; Desrumaux C; Châtenet-Duchêne L; Courtois M; Farnier M; Jacotot B; Braschi S; Gambert P
    Atherosclerosis; 1999 Apr; 143(2):415-25. PubMed ID: 10217372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical study on the effect of simvastatin on butyrylcholinesterase activity.
    Muacević-Kataneca D; Bradamante V; Reinec Z; Sucić M; Poljicanin T; Busljeta I; Metelko Z
    Arzneimittelforschung; 2005; 55(5):271-5. PubMed ID: 15960426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of paraoxonase 1 is associated with HDL remodeling ex vivo.
    Gugliucci A
    Clin Chim Acta; 2014 Feb; 429():38-45. PubMed ID: 24280342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of simvastatin on the apparent size of LDL particles in patients with type IIB hyperlipoproteinemia.
    Zhao SP; Hollaar L; van 't Hooft FM; Smelt AH; Gevers Leuven JA; van der Laarse A
    Clin Chim Acta; 1991 Dec; 203(2-3):109-17. PubMed ID: 1777975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
    Avellone G; Di Garbo V; Guarnotta V; Scaglione R; Parrinello G; Purpura L; Torres D; Campisi D
    Int Angiol; 2010 Dec; 29(6):514-24. PubMed ID: 21173733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of probucol on antioxidant properties of HDL in patients with heterozygous familial hypercholesterolemia.
    Inagaki M; Nakagawa-Toyama Y; Nishida M; Nakatani K; Nakaoka H; Kawase M; Kawase R; Tsubakio-Yamamoto K; Masuda D; Ohama T; Matsuyama A; Ishigami M; Komuro I; Yamashita S
    J Atheroscler Thromb; 2012; 19(7):643-56. PubMed ID: 22785024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of simvastatin treatment on the electronegative low-density lipoprotein present in patients with heterozygous familial hypercholesterolemia.
    Sánchez-Quesada JL; Otal-Entraigas C; Franco M; Jorba O; González-Sastre F; Blanco-Vaca F; Ordóñez-Llanos J
    Am J Cardiol; 1999 Sep; 84(6):655-9. PubMed ID: 10498134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia.
    Paragh G; Törocsik D; Seres I; Harangi M; Illyés L; Balogh Z; Kovács P
    Curr Med Res Opin; 2004 Aug; 20(8):1321-7. PubMed ID: 15324535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
    Bruckert E; De Gennes JL; Malbecq W; Baigts F
    Clin Cardiol; 1995 Nov; 18(11):621-9. PubMed ID: 8590530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of simvastatin in familial hypercholesterolemia on the affinity of electronegative low-density lipoprotein subfractions to the low-density lipoprotein receptor.
    Benítez S; Ordóñez-Llanos J; Franco M; Marín C; Paz E; López-Miranda J; Otal C; Pérez-Jiménez F; Sánchez-Quesada JL
    Am J Cardiol; 2004 Feb; 93(4):414-20. PubMed ID: 14969613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of HDL-bound and free PON1 on copper-induced LDL oxidation.
    Bayrak A; Bayrak T; Bodur E; Kılınç K; Demirpençe E
    Chem Biol Interact; 2016 Sep; 257():141-6. PubMed ID: 27510818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.